Clinical Kidney Journal最新文献

{"title":"Size-selective glomerular filtration as a hallmark of premature kidney ageing in nondiabetic individuals.","authors":"Agne Laucyte-Cibulskiene, Christopher Nilsson, Amra Jujic, Hannes Holm, Anders Christensson","doi":"10.1093/ckj/sfaf208","DOIUrl":"10.1093/ckj/sfaf208","url":null,"abstract":"<p><strong>Background: </strong>During the last decade, evidence has emerged on selective glomerular hypofiltration syndromes (SGHS), defined by selectively reduced filtration of middle-sized molecules irrespective of kidney function and resulting in a low ratio between cystatin C- and creatinine-based estimated glomerular filtration rates (eGFRcys/eGFRcr). We aimed to examine whether SGHS is a hallmark of premature kidney ageing manifested by accumulation of advanced glycation end-products (AGEs) and endothelial dysfunction in a population free from chronic kidney disease and diabetes.</p><p><strong>Methods: </strong>A total of 3804 participants of The Malmö Offspring Study (MOS) underwent AGE (skin autofluorescence acquired), eGFRcys and eGFRcr measurements. AGEs ≥1.6 were categorized as high, and AGEs <1.6 as normal. Reactive hyperemia index (RHI) was available in 2204 participants; RHI <1.67 indicated endothelial dysfunction (ED), and RHI ≥1.67 normal endothelial function (EF). Combining AGEs and RHI, four groups were compared: (group 1) AGEs <1.6 and EF, (group 2) AGEs <1.6 and ED, (group 3) AGEs ≥1.6 and EF, and (group 4) AGEs ≥1.6 and ED.</p><p><strong>Results: </strong>Lower eGFRcys/eGFRcr ratio was associated with an increase in AGEs in men and women. After adjusting for cardiovascular factors, lower eGFRcys/eGFRcr ratio was associated with AGE accumulation in men older than 30 years. The 'AGEs ≥1.6 and ED' and 'AGEs ≥1.6 and EF' groups showed the highest prevalence of eGFRcys/eGFRcr under 0.9 (in men, 22% vs 19.7%, in women 19.5% vs 16%, respectively).</p><p><strong>Conclusions: </strong>Accumulation of AGEs resulting from SGHS leads to age dependent changes in glomerular basement membrane and increased selectivity for middle-sized molecules. Presence of these findings in younger individuals supports the hypothesis that SGHS is a model of early kidney ageing, occurring before decline in kidney function.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 8","pages":"sfaf208"},"PeriodicalIF":4.6,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12451684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted-release formulation budesonide.","authors":"Qinlan Chen, Pei Chen, Rong He, Jincan Zan, Xue Shen, Jicheng Lv, Hong Zhang","doi":"10.1093/ckj/sfaf203","DOIUrl":"10.1093/ckj/sfaf203","url":null,"abstract":"<p><strong>Background: </strong>Targeted release formulation (TRF) budesonide (Nefecon), targeting galactose-deficient immunoglobulin A1 (Gd-IgA1) production and IgA immune complex formation, has been approved for IgA nephropathy (IgAN) treatment. In this study we explored whether early changes in these biomarkers can predict the clinical response to Nefecon therapy.</p><p><strong>Methods: </strong>Plasma samples from 27 IgAN patients treated with Nefecon and followed at least 6 months were collected during routine visits. We measured the levels of Gd-IgA1 and poly-IgA during the treatment, analysing the association between their baseline levels or changes and proteinuria reduction.</p><p><strong>Results: </strong>The mean proteinuria level was 1.3 ± 0.8 g/day and the estimated glomerular filtration rate was 47.1 ± 21.7 ml/min/1.73 m² at baseline. During the follow-up, proteinuria slowly decreased, with alterations of -0.12 g/day, -0.42 g/day, -0.58 g/day and -0.86 g/day at 3, 6, 9 and 12 months, respectively. The plasma levels of Gd-IgA1, poly-IgA and total IgA decreased after Nefecon treatment, with an obvious decrease at 2 months in Gd-IgA1 by -1067.3 ng/ml and poly-IgA by -1.18 mg/l. All biomarker reductions were strongly associated with a proteinuria decrease (<i>P</i> < .0001). Importantly, the early reduction in poly-IgA during the first 2 months was associated with a proteinuria reduction at 6 months (<i>R</i> = 0.47, <i>P</i> = .01). Similar trends were observed for Gd-IgA1, though not statistically significant.</p><p><strong>Conclusions: </strong>The early changes in Gd-IgA1 or poly-IgA, especially poly-IgA, were associated with future proteinuria reduction, supporting the potential of Gd-IgA1 and poly-IgA as biomarkers for predicting Nefecon response in IgAN.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 7","pages":"sfaf203"},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneity of regional and national hospitalization burden of lupus nephritis and systemic lupus erythematous.","authors":"Alejandro Avello, Raúl Fernández-Prado, Daria Abasheva, Ignacio Mahillo, Miguel Ángel González-Gay, Catalina Martín-Cleary, José Miguel Arce-Obieta, María Vanessa Pérez-Gómez, Beatriz Fernández-Fernández, Alberto Ortiz","doi":"10.1093/ckj/sfaf162","DOIUrl":"10.1093/ckj/sfaf162","url":null,"abstract":"<p><strong>Background: </strong>Differences between regional healthcare systems in the in-hospital burden and care of systemic lupus erythematosus (SLE) and lupus nephritis (LN) are poorly characterized. Their analysis may provide benchmarking opportunities that improve the quality and sustainability of care.</p><p><strong>Methods: </strong>We retrospectively investigated the hospitalization burden of SLE and LN in 2019-2021 across Spanish regional healthcare systems using the Spanish National Hospital Discharge Records database (RAE-CMBD) and National Statistics Institute (INE) data.</p><p><strong>Results: </strong>Of 66 262 724 hospitalization episodes from 644 public and private hospitals, 10 781 had a primary diagnosis of SLE, of which 2481 (23%) were for LN. The mean annual nationwide hospitalization case incidence was 70.61 and 1.75 per 100 000 population for SLE and LN, respectively. Regional differences were large: 48.0-fold and 6.9-fold between regions with the highest and lowest incidence for SLE and LN, respectively. In multivariate analysis, net household income and percentage of foreign-born population were associated with the number of SLE and LN hospitalization episodes. Internal medicine managed 28% of SLE and 15% of LN hospitalizations, nephrology 14% and 56% and rheumatology 23% and 11%, respectively, but there were large regional differences. The mean SLE and LN stays were 8.85 and 6.92 days (5.47 and 5.41 for nephrology and 11.18 and 11.83 for internal medicine), respectively. The average all patient refined diagnosis related groups (APR-DRGs) cost per episode was €2408 for SLE and €3563 for LN. The average yearly costs were €167 985 per million population (pmp) for SLE hospitalizations (4.32-fold differences between regions) and €60 825 pmp for LN hospitalizations (4.20-fold differences between regions). Large differences between regions were observed in the cost burden pmp relative to household income (4.70-fold for LN and 4.13-fold for SLE).</p><p><strong>Conclusion: </strong>In real-world clinical practice, the burden of in-hospital care of LN and SLE is heterogeneous across and within regional healthcare systems, offering the opportunity to benchmark best practice, optimize care and improve outcomes.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 7","pages":"sfaf162"},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: The management of chronic kidney disease in primary care in Denmark: patient characteristics, treatment, follow-up, progression and referral.","authors":"","doi":"10.1093/ckj/sfaf177","DOIUrl":"https://doi.org/10.1093/ckj/sfaf177","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/ckj/sfae393.].</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 6","pages":"sfaf177"},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of changes in potassium intake on blood pressure: a dose-response meta-analysis of randomized clinical trials (2000-2024).","authors":"Maelys Granal, Victoria Sourd, Michel Burnier, Jean Pierre Fauvel, Arthur Gougeon","doi":"10.1093/ckj/sfaf173","DOIUrl":"10.1093/ckj/sfaf173","url":null,"abstract":"<p><strong>Background: </strong>Over the past three decades, the prevalence of hypertension in adults has doubled worldwide, surging from 650 million to 1.3 billion cases between 1990 and 2019. Sodium reduction is a cornerstone of non-pharmacological strategies for managing hypertension. However, recent guidelines increasingly emphasize the importance of boosting potassium intake, supported by robust evidence of its cardiovascular benefits. Despite this, the precise dose-dependent effects of potassium on blood pressure (BP) remain inadequately defined.</p><p><strong>Methods: </strong>We conducted a systematic review of randomized controlled trials (RCTs) published between 2000 and 2024 to evaluate the impact of potassium supplementation alone-assessed solely via 24-h urinary potassium excretion-on BP. A dose-response meta-analysis was performed using linear, quadratic, and one-stage cubic spline regression models. Subgroup analyses were carried out based on subjects with or without hypertension.</p><p><strong>Results: </strong>Our meta-analysis included 10 RCTs, comprising 4 studies on subjects without hypertension and 6 studies on subjects with hypertension. The dose-response relationship varied according to BP status. In subjects without hypertension, potassium supplementation had a modest negative linear effect on BP. In contrast, subjects with hypertension exhibited a markedly higher reduction in BP. Specifically, a 50 mmol/day increase in urinary potassium excretion was associated with a 0.5 mmHg reduction in systolic BP (SBP) and a 0.12 mmHg reduction in diastolic BP (DBP) in subjects without hypertension, and a 5.3 mmHg reduction in SBP and a 3.62 mmHg reduction in DBP in subjects with hypertension.</p><p><strong>Conclusion: </strong>This meta-analysis highlights the dose-response relationship between potassium supplementation and BP reduction, particularly in subjects with hypertension. While the findings offer valuable insights for refining dietary guidelines, caution is warranted due to the limited number of RCTs included in the analysis.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 7","pages":"sfaf173"},"PeriodicalIF":3.9,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal vascular endothelial growth factor inhibitor systemic and renal toxicity registry.","authors":"Matthew D Nguyen, Ryan Fekrat, Caroline Gee, Arif Nihat Demirci, Sohrab Kharabaf, Dao Le, Mina Tadros, Vu Q Nguyen, Samir Patel, Tai Truong, Rebecca Ahdoot, Ira B Kurtz, Michael Kerr, Abanoub Massoud, Ramy Hanna","doi":"10.1093/ckj/sfaf206","DOIUrl":"10.1093/ckj/sfaf206","url":null,"abstract":"<p><strong>Background: </strong>Intravitreal vascular endothelial growth factor inhibitors (IVEGFi) are used in the treatment of diabetic retinopathy, age-related macular degeneration (AMD) and central retinal vein obstruction. As we have previously reported, there are an increasing number of cases documenting IVEGFi with renal injury and increased concentrations in the serum. To assess this claim, we have developed a novel reporting system through an electronic registry for cases of suspected VEGFi injury.</p><p><strong>Methods: </strong>A website with multiple data protection sets was created to educate, promote awareness and capture patient cases of suspected IVEGFi toxicity. The website displays the molecular biology of VEGF signaling, the process of absorption into the bloodstream, and study reports showing risks on case, cohort and epidemiologic levels. A Health Insurance Portability and Accountability Act (HIPAA)-compliant patient intake form was designed to collect renal, cardiovascular, cerebrovascular, renal biopsy and function data along with drug type, indication and frequency of administration.</p><p><strong>Results: </strong>In our updated cohort we added 16 total cases from the literature showing signs of renal injury from the patient population receiving VEGFi. In current literature, 46 cases of VEGFi-related renal injury have been documented. To them, we add our 16 cases for a total of 62 cases.</p><p><strong>Conclusion: </strong>The current database for VEGFi-related nephrotoxicity constitutes the largest case series presented for this condition. This study opens the door for future studies to evaluate what subgroups experience acute kidney injury, proteinuria and hypertension exacerbations. Additionally, we may expand on our database to include timeline markers for symptomatic-correlative VEGFi usage and, in time, predictive measures on a larger scale to correlate comorbidity/drug use with drug effect and mechanism of action.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 8","pages":"sfaf206"},"PeriodicalIF":4.6,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal patterns of fluid overload, blood volume and vascular refilling: a prospective study in patients on maintenance hemodialysis.","authors":"Sebastian Mussnig, Simon Krenn, Max Waller, Michael Schmiedecker, Amelie Kurnikowski, Janosch Niknam Saeidi, Luis Naar, Christopher C Mayer, David Keane, Daniel Schneditz, Manfred Hecking, Leszek Pstras","doi":"10.1093/ckj/sfaf199","DOIUrl":"10.1093/ckj/sfaf199","url":null,"abstract":"<p><strong>Introduction: </strong>Patients on maintenance hemodialysis accumulate excess fluid between treatments. Intradialytic removal of fluid via ultrafiltration is partly compensated by vascular refilling from the interstitial space. Associations between whole-body fluid status and blood volume were previously investigated on the population level. The aim of this observational cohort study was to assess longitudinal changes in fluid compartment volumes on an intra-patient level.</p><p><strong>Methodology: </strong>Pre-dialysis bioimpedance spectroscopy measurements and absolute blood volume estimations were conducted in maintenance hemodialysis patients during 14 consecutive dialysis treatments over 5 weeks. Blood volume was determined using the dialysate bolus method. Longitudinal changes were evaluated using linear mixed models. Correlations were analyzed with repeated measures correlation coefficients ([Formula: see text]).</p><p><strong>Results: </strong>Twenty-five patients were included in the final analysis [88% male, median (quartile 1, quartile 3) age and dialysis vintage of 66.0 years (48.0, 74.0) and 23.5 months (13.5, 34.5), respectively]. Pre-dialysis fluid overload significantly decreased from the first to the third treatment within the week (<i>β</i> = -0.38, <i>P</i> < .01) with no significant within-week changes in euvolemic body mass (<i>β</i>= -0.04, <i>P</i> = .78) or absolute blood volume at treatment start (<i>β</i> = -0.06, <i>P</i> = .65). Fluid overload did not correlate with absolute ([Formula: see text] = 0.10, <i>P</i> = .65) or specific blood volume ([Formula: see text]=0.06, <i>P</i> = .78) at treatment start on an intra-patient level, but correlated moderately with refilling volume ([Formula: see text] = 0.46, <i>P</i> < .01).</p><p><strong>Conclusions: </strong>The observed lack of intra-patient correlations between pre-dialysis fluid overload and blood volume suggests that excess fluid may not necessarily accumulate proportionally in the interstitial and intravascular space, thus challenging previous assumptions regarding within-week changes in fluid compartments.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 8","pages":"sfaf199"},"PeriodicalIF":4.6,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of individual socioeconomic deprivation on hemodialysis care and patient behavior: a multicenter French study (Precadia).","authors":"Yves Dimitrov, François Chantrel, Thierry Krummel, Clotilde Muller, Emmanuelle Charlin, Alexandre Klein, Thierry Hannedouche","doi":"10.1093/ckj/sfaf201","DOIUrl":"10.1093/ckj/sfaf201","url":null,"abstract":"<p><strong>Background: </strong>Socioeconomic deprivation (SED) is increasingly recognized as a key determinant of morbidity and mortality among patients receiving hemodialysis. However, most prior studies have relied on area-level socioeconomic indicators and have been conducted outside of Europe.</p><p><strong>Objective: </strong>To assess whether individual-level socioeconomic status, measured using the EPICES score, influences healthcare quality and patient behaviors in adults undergoing maintenance hemodialysis in northeastern France.</p><p><strong>Methods: </strong>This multicenter observational study was conducted across five dialysis units. Adult patients with end-stage renal disease receiving hemodialysis for ≥3 months were enrolled. The EPICES score was used to assess individual SED, and patients were stratified into deprived (P+) and non-deprived (P-) groups based on the median score. Clinical, biochemical, and behavioral variables were compared between groups.</p><p><strong>Results: </strong>A total of 401 patients were included (mean age 68.5 years; 60% male). The median EPICES score was 33.1 (mean 35.8 ± 18.9). Compared with P - patients, P + patients had a significantly longer dialysis vintage (76.3 vs. 73.9 months, <i>p</i> = .002), higher normalized protein catabolic rate (nPCR; 1.28 vs. 1.06 g/kg/day, <i>p</i> = .007), higher CRP concentrations (14.3 ± 4.1 vs. 9.56 ± 0.8 mg/L, <i>p</i> < .02 ), and greater smoking prevalence (34% vs. 15%, <i>p</i> = .004). No significant differences were observed in albumin and hemoglobin levels, erythropoietin (EPO) dosing, or the frequency of missed dialysis sessions. The CRP × P + interaction on nPCR was significant, suggesting that systemic inflammation could modify the association between deprivation and protein catabolism.</p><p><strong>Conclusion: </strong>Individual-level SED was associated with differences in health behaviors but not in the quality of physician-driven dialysis care. These findings challenge the notion that deprived patients inherently receive lower-quality clinical care and emphasize the need for targeted strategies that address patient-dependent behavioral factors.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 8","pages":"sfaf201"},"PeriodicalIF":4.6,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12374186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal vein evaluation in venous excess ultrasound (VExUS): is it necessary?","authors":"Masafumi Sakai, Keisuke Yoshida, Kana Shirai, Fumiya Kitano, Yugo Shibagaki, Masahiko Yazawa","doi":"10.1093/ckj/sfaf205","DOIUrl":"10.1093/ckj/sfaf205","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 7","pages":"sfaf205"},"PeriodicalIF":3.9,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12264486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of obinutuzumab in active lupus nephritis.","authors":"Corina-Daniela Ene, Annette Bruchfeld","doi":"10.1093/ckj/sfaf161","DOIUrl":"10.1093/ckj/sfaf161","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 7","pages":"sfaf161"},"PeriodicalIF":3.9,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}